StockNews.com Begins Coverage on bluebird bio (NASDAQ:BLUE)

Investment analysts at StockNews.com started coverage on shares of bluebird bio (NASDAQ:BLUE) in a report issued on Friday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Other equities research analysts have also issued reports about the stock. JPMorgan Chase & Co. raised shares of bluebird bio from an “underweight” rating to a “neutral” rating in a report on Monday, February 24th. Barclays boosted their target price on shares of bluebird bio from $2.00 to $40.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 31st. Wells Fargo & Company lowered their price target on shares of bluebird bio from $40.00 to $5.00 and set an “equal weight” rating for the company in a report on Monday, February 24th. Finally, Baird R W downgraded bluebird bio from a “strong-buy” rating to a “hold” rating in a report on Friday, February 21st. One investment analyst has rated the stock with a sell rating, six have given a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $51.00.

bluebird bio Price Performance

Shares of BLUE stock opened at $4.08 on Friday. The stock’s fifty day moving average is $5.53 and its 200-day moving average is $7.75. The stock has a market capitalization of $39.67 million, a PE ratio of -0.11 and a beta of 0.76. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.33 and a current ratio of 0.51. bluebird bio has a 52 week low of $3.56 and a 52 week high of $28.60.

Institutional Trading of bluebird bio

Several institutional investors have recently modified their holdings of the business. Regeneron Pharmaceuticals Inc. bought a new position in bluebird bio during the 4th quarter worth $175,000. State Street Corp raised its position in shares of bluebird bio by 1.1% during the third quarter. State Street Corp now owns 3,841,923 shares of the biotechnology company’s stock worth $1,996,000 after acquiring an additional 43,382 shares during the last quarter. Captrust Financial Advisors lifted its stake in shares of bluebird bio by 48.2% in the third quarter. Captrust Financial Advisors now owns 237,648 shares of the biotechnology company’s stock worth $123,000 after acquiring an additional 77,293 shares during the period. Verition Fund Management LLC acquired a new position in shares of bluebird bio in the third quarter worth approximately $42,000. Finally, Geode Capital Management LLC boosted its holdings in bluebird bio by 3.7% in the third quarter. Geode Capital Management LLC now owns 4,683,042 shares of the biotechnology company’s stock valued at $2,433,000 after acquiring an additional 166,771 shares during the last quarter. Institutional investors own 87.43% of the company’s stock.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.